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Abstract
Stereotactic body radiotherapy is being investigated in nodal oligometastatic prostate cancer recurrences as
an alternative to systemic treatment. This approach yields excellent in-field control and a low toxicity profile. In
selected cases, this approach might also defer palliative androgen deprivation therapy.
Background: The purpose of the study was to evaluate the prostate serum antigen (PSA) response, local control,
progression-free survival (PFS), and toxicity of stereotactic body radiotherapy (SBRT) for lymph node (LN) oligor-
ecurrent prostate cancer. Patients and Methods: Between May 2012 and October 2015, 124 lesions were treated in
94 patients with a median dose of 24 Gy in 3 fractions. Seventy patients were treated for a single lesion and 25 for > 1
lesion. In 34 patients androgen deprivation (AD) was combined with SBRT. We evaluated biochemical response
according to PSA level every 3 months after SBRT: a 3-month PSA decrease from pre-SBRT PSA of more than 10%
identified responder patients. In case of PSA level increase, imaging was performed to evaluate clinical progression.
Toxicity was assessed every 6 to 9 months after SBRT. Results: Median follow-up was 18.5 months. In 13 patients
(14%) Grade 1 to 2 toxicity was reported without any Grade 3 to 4 toxicity. Biochemical response, stabilization, and
progression were observed in 64 (68%), 10 (11%), and 20 (21%) of 94 evaluable patients. Clinical progression was
observed in 31 patients (33%) after a median time of 8.1 months. In-field progression occurred in 12 lesions (9.7%).
Two-year local control and PFS rates were 84% and 30%, respectively. Age older than 75 years correlated with better
biochemical response rate. Age older than 75 years, concomitant AD administered up to 12 months, and pelvic LN
involvement correlated with longer PFS. Conclusion: SBRT is safe and offers good in-field control. At 2 years after
SBRT, 1 of 3 patients is progression-free. Further investigation is warranted to identify patients who benefit most from
SBRT and to define the optimal combination with AD.
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For years, androgen deprivation (AD) has been considered a first-
choice approach to recurrent prostate cancer (PC)1 with significant
side effects and a deterioration in the quality of life.2 Evolution of
imaging and radiotherapy (RT) modalities has allowed the diagnosis
of low-burden recurrent cancer and enabled precise tumor-targeting
using high doses per fraction (stereotactic ablative body RT
[SBRT]). Interestingly, whole-body magnetic resonance imaging
with diffusion-weighted noninvasive imaging of metastatic landing
sites shows that 28% of the metastatic hormone-naive PC and 52%
of the metastatic castration-resistant PC might be labeled as oligo-
metastatic PC.3 The treatment armamentarium for metastatic PC
has changed significantly in the past decade, ranging from chemo-
hormonal therapy to a metastasis-directed approach.4,5 The po-
tential elimination of all macroscopic cancer foci can reduce the
burden of systemic therapies for recurrent/metastatic PC.5-8 Indeed
51% of oligometastatic PC patients were progression-free 1 to 3
years after salvage metastasis-directed therapy.5 PC is a radiosensi-
tive disease and RT commonly plays a curative role in localized
PC.1,6 Theoretically, small-volume high-dose SBRT to limit re-
currences from PC might reduce the tumor load prolonging the
progression-free interval.
Stereotactic ablative body RT can be performed using linear
accelerators (linacs) or dedicated machines such as GammaKnife or
CyberKnife (Accuray Inc, Sunnyvale, CA).9 Despite numerous re-
ports on SBRT for various metastatic tumors, the experience of
SBRT for metastatic PC is limited.8,10-16 Most of PC SBRT reports
include nonmetastatic organ-confined patient series.17-20
Initially, we used linac-based SBRT to treat oligometastases from
PC. In 2007 a collaboration between the European Institute of
Oncology, Milan, Italy and the CyberKnife Center Centro Diag-
nostico Italiano, Milan, included a prospective evaluation of the
outcome. Our previous reports on SBRT for recurrent PC involving
isolated lymph node (LN) metastases, showed excellent in-field
control and a low toxicity profile.11,20,21 These findings were
confirmed in our subsequent larger series.12,13 In this report we
present a cohort of 94 patients (124 LNs) treated at the European
Institute of Oncology with the Vero system (Mitsubishi Heavy
Industries, Ltd., Tokyo, Japan and Brainlab AG, Feldkirchen,
Germany) or CyberKnife-based SBRT for LN oligorecurrent PC.
The patients from our previous reports are not included in this
study (the patients from our previous series were treated using linac-
based SBRT or CyberKnife-based SBRT at the Centro Diagnostico
Italiano). The data of 41 patients from the current series have been
used for the multi-institutional analysis accepted for the eighth
European Multidisciplinary Meeting on Urological Cancers 2016
presentation.14
Patients and Methods
Inclusion Criteria
The criteria for inclusion in the study were: (1) isolated oligo-
metastatic ( 5) PC LN recurrence; (2) treatment with SBRT be-
tween May 2012 and October 2015; (3) all cases were approved by
the multidisciplinary uro-oncology board; (4) written informed
consent (wIC) for the SBRT; and (5) wIC for the use of the ano-
nymized data for research or educational purpose. The study was a
part of general SBRT and image-guided RT research notified to the- Clinical Genitourinary Cancer August 2017Italy (notifications 79/10, 86/11, 87/11, and 93/11).
The diagnosis of a clinically evident LN recurrent PC was on the
basis of biochemical progression and imaging studies. Total body
staging was required to exclude other disease sites using [11C]
choline positron emission tomography (PET)/computed tomogra-
phy (CT), a CT scan of the thorax and abdomen and/or magnetic
resonance imaging (MRI). LNs were classified as “pelvic” or regional
(pLN) and “extrapelvic” or metastatic (eLN).
Any kind of previous PC therapy was permissible. Those who
had begun systemic treatment when diagnosed with recurrent PC
(which was given concomitantly with the SBRT) were admitted. No
other local therapy for recurrent lesions was permitted.
Treatment Protocol
The SBRT dose prescribed was dependent on the volume of the
LN and its location. In case of unfavorable location or reirradiation,
lower dose per fraction or lower total dose was administered.
For CyberKnife SBRT, the Multiplan treatment planning system
(version 2.0.5 Accuray) was used. Photon energy of 6 MV was used.
Fiducials were not used. Xsight Spine detecting system (Accuray) was
applied. All patients were immobilized during CT simulation and
treatment, using a customized external vacuum-type cast. The gross
tumor volume (GTV) was contoured on the CT scan and a 2-mm
margin was added to the GTV to obtain the planning target vol-
ume (PTV). During the irradiation the patient position is controlled
by the spine tracking system imaging (on average every 50 seconds).
The dose was prescribed to the mean 77.5% isodose using a non-
isocentric and noncoplanar CyberKnife treatment technique.
For Vero system SBRT, Iplannet (version 4.5.3; BrainLab) was
used. All patients were immobilized during CT simulation and
treatment using the Combifix (CIVCO Medical Solutions) device.
Seven infrared markers were put on the chest wall for CT simulation
and treatment session to correct the setup errors and the shifts
during the treatment. The GTV was contoured on the CT scan and
a 3-mm margin was added to the GTV to compensate for the
geometrical penumbra of the system. These relatively narrow mar-
gins were feasible because of the high precision of CyberKnife and
BrainLab Vero treatment delivery.22,23 Several coplanar and no
coplanar dynamic arcs were used for treatment planning. During
Vero system beam delivery, the ExacTrac (BrainLab) system on the
basis of the infrared markers, was used to monitor the position of
the target.11 Cone-beam CT (CBCT) was performed before every
Vero system session. Daily treatment times were kept at less than 15
to 20 minutes.
Organs at risk depended on the localization of the LN. For pLN,
the rectum (external contour), urinary bladder (external contour),
urethra, femoral heads, and small bowel were contoured. The dose
volume constraints of Timmerman et al were applied.24 Particular
attention was paid to patients who had already been irradiated and
SBRT was used for in-field LN recurrence: for all those patients the
original treatment plans were reviewed.
After SBRT, a prostate serum antigen (PSA) test was performed
every 3 months (first evaluation after SBRT was performed at 3
months) and clinical examination every 6 months. Biochemical
response was defined a reduction of PSA value > 10% (complete if
> 50%) with respect to pre-SBRT PSA value. Stabilization referred
Table 1 Patient and Tumor Characteristics (N[ 94 Patients)
Characteristic Value
Initial Treatment
RRP with or without AD 39 (41.5%)
RRP with RT with or without AD 34 (36.2%)
RT with or without AD 19 (20.2%)
Brachytherapy 2 (2.1%)
Initial PSA (ng/mL)a
n 88 (6 missing data)
Median (IQR) 9.8 (6.1-18.0)
Initial Gleason Scoreb
n 89 (5 missing data)
Median (IQR) 7 (7-8)
Initial Tc
T1 10 (10.6%)
T2 29 (30.9%)
T3 50 (53.2%)
T4 2 (2.1%)
T unknown 3 (3.2%)
SBRT Treatment
Vero system (Mitsubishi-Brainlab) 84 (89.4%)
CyberKnife (Accuray) 10 (10.6%)
Age at the SBRT, Years
n 94
Mean  SD 69.7 (8.0)
Median (IQR) 70 (65-76)
KPS at the SBRT
80 2 (2.1%)
90 26 (27.7%)
100 66 (70.2%)
Interval Between Diagnosis of Prostate
Cancer and SBRT, Months
N 94
Mean  SD 74.8 (47.6)
Median (IQR) 61 (41-109)
Abbreviations: AD ¼ androgen deprivation; IQR ¼ interquartile range; KPS ¼ Karnofsky
performance status; PSA ¼ prostate serum antigen; RRP ¼ radical retropubic prostatectomy;
RT ¼ radiotherapy; SBRT ¼ stereotactic body radiotherapy.
aInitial PSA available in 88 patients.
bInitial Gleason Score available in 90 patients (%).
cClinical/pathological T.
Barbara Alicja Jereczek-Fossa et alto 3-month PSA between 10% and 10% of the pre-SBRT
value.13 A PSA increase > 10% was classified as biochemical pro-
gression. In case of biochemical failure, radiological (CT or MRI) or
[11C]choline PET/CT re-evaluation was requested.
Statistical Analysis
Continuous data were expressed as mean  SD if normally
distributed, as median and range or interquartile range otherwise;
categorical variables were expressed as percentages. Progression-free
survival (PFS) and local progression were calculated from date of
the end of SBRT treatment to the date of biochemical or clinical
progression, respectively, or latest follow-up. In the analysis of local
progression reported in the treatment field, any other clinical or
biochemical out-of-field (ie, planning treatment volume or PTV)
event, as well as any deaths, were considered as competing events.25
Because of the very small number of deaths, no overall survival rate
was calculated. Survival data were represented using the
KaplaneMeier approach26 with differences between groups evalu-
ated using the log rank test. Prognostic factors were evaluated using a
multivariate proportional hazard Coxmodel.27 Factors were included
in the multivariable models if its univariate P value was  .20.
Covariates included in themodels were selected among the following:
primary treatment (surgery vs. surgery with RT vs. RT), initial
Gleason score, initial T status (T1, T2, T3/4), SBRT treatment
machine (Vero system vs. CyberKnife), age at the time of SBRT,
concomitant AD (no vs.  12 months vs.  12 months), Karnofsky
score, SBRT as first treatment or no, number of lesions per patient,
and pLN versus eLN. Results from Cox multivariable models were
presented in terms of hazard ratio and 95% confidence interval along
with the Wald test P value. The Gray model,28 which takes
competing events into account, was performed for the analysis of local
events. The significance of differences was assessed using Pearson c2
for categorical variables. Factors associated with response to treatment
were evaluated using logistic regression. The analyses were performed
with the SAS statistical software (version 9.2; SAS Institute Inc, Cary,
NC). The plot and estimates of the cumulative incidence for local
control were performed using the R software (http://cran.r-project.
org) with the cmprsk library developed by Gray (https://cran.r-
project.org/web/packages/cmprsk/cmprsk.pdf). All reported P
values were 2-sided.
Results
Patients
Ninety-four patients with LN oligorecurrent PC (124 LNs) were
included in the study between May 2012 and October 2015. The
median age at the time of the SBRT was 70.7 years. All baseline
characteristics are shown in Table 1. The median interval between
the diagnosis of PC and the first day of SBRT treatment was 49.6
months (range, 27.2-122.4 months).
Total body staging was performed to exclude other sites of dis-
ease: 90, 3, and 1 patient underwent [11C]choline PET/CT, MRI,
and CT examination, respectively.
Treatment
CyberKnife-SBRT or Vero system-SBRT was applied in 10
(10.6%) and 84 (89.4%) patients, respectively. Seventy patients
(74.5%) had single LN and in 24 (25.5%) more than 1 (2e4)LNs were treated concomitantly (synchronous SBRT). Only 1
patient had 4 LNs involved. Five and 1 patient were treated with
2 and 3 SBRT treatments (metachronous SBRT) for different LN
recurrences, respectively. In 2 cases SBRT was repeated to the same
LN because of in-field relapse.
Median PSA pre-SBRT was 3.5 ng/mL. In 9 patients (9.6%)
SBRT was performed as a reirradiation (the recurrent lesion was
situated in the previously irradiated volume) and for 86 patients
(90.4%) SBRT was a first radiation treatment.
For 34 patients (36.2%), some form of neoadjuvant and
concomitant AD was combined with SBRT treatment (median
duration, 14.5 months). One patient was castration-resistant and
received a taxane-based chemotherapy regimen before SBRT.Clinical Genitourinary Cancer August 2017 - e625
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e626All patients completed the SBRT. No protocol violation was
recorded. The median dose was 24 Gy (range, 15e36 Gy) in 3
fractions. The median biological effective dose was 152
(range, 65e324) calculated on the basis of a/b ¼ 1.5 Gy. The
median duration of the SBRT course was 3 days (the treatment was
given on consecutive days in most patients; Table 2).
Follow-up
No patient was lost to follow-up. The median follow-up period
was 18.5 months (range, 3e42 months). At the time of the analysis,
32 (34%) patients were alive with no evidence of disease, 60
(63.8%) were alive with clinically evident disease, and 2 (2.2%)
patients died (Table 3).Table 2 Patient and SBRT Treatment Characteristics (N[ 94
patients,124 Lesions)
Characteristic Value
Pre-SBRT PSA, ng/mL
N 94
Median (IQR) 3.5 (1.6-6.1)
Number of Lymph Nodes at SBRT
1 70 (74.5%)
2 19 (20.2%)
3 4 (4.3%)
4 1 (1.0%)
Total Lymph Nodes (Per Lesion) 124
Pelvic 75 (60.5%)
Extrapelvic 49 (39.5%)
SBRT as
1st Treatment 85 (90.4%)
Reirradiation 9 (9.6%)
Concomitant Systemic Treatment
Yes (ADT) 34 (36.2%)
Yes (Other) 3 (3.2%)
No 57 (60.6%)
SBRT Data (Per Lesion)
Total median dose (range), Gy 24 (15-36)
Median dose per fraction (range) 8 (5-12)
Median number of fractions (range) 3 (3-6)
SBRT Regimen (Per Lesion), n
5 Gy per 3 fractions 2
5 Gy per 5 fractions 8
6 Gy per 3 fractions 3
6 Gy per 4 fractions 2
6 Gy per 5 fractions 7
8 Gy per 3 fractions 65
8 Gy per 4 fractions 3
10 Gy per 3 fractions 23
12 Gy per 3 fractions 2
Other 9
Abbreviations: ADT ¼ androgen deprivation therapy; IQR ¼ interquartile range; PSA ¼ prostate
serum antigen; SBRT ¼ stereotactic body radiotherapy.
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Response. At 3 months PSA evaluation was performed: biochem-
ical response (BR) was defined as a PSA level reduction > 10% of
pre-SBRT value (complete if > 50%), stabilization referred to pre-
SBRT PSA level  10%, and progression if PSA was 10% greater
than pre-SBRT PSA value. BR or stable disease was observed in 74 of
94 patients (78.7%). In 20 patients (21.3%) progressive disease was
observed. During follow-up, clinical progression was observed in 31
patients (33%) after a median time of 8.1 months (range, 2.3e31.8
months) from SBRT. Considering all progressive disease events (61
patients, ie, 20 and 41 patients with progression at first evaluation
and during follow-up, respectively), 30 (32%) patients showed only
biochemical progression, and 31 (33%) biochemical and clinical
progression. Eleven patients (12%) had locoregional recurrence and
20 patients (21%) had distant metastases of whom 10 showed only
LN progression. In-field progression was observed in 12 of 124
irradiated LNs (9.7%) after a median time of 7 months (range, 4-22
months). In-field progressions were 4 (3.2%) in the subgroup of
patients who received concomitant AD. Two-year local control and
PFS probability were 84% and 30%, respectively (Figures 1 and 2).
In patients treated with concomitant AD, 2-year PFS and local
control probability were 49.4% and 27.2%, respectively. In patients
treated with SBRT alone, 2-year PFS and local control probability
were 22.6% and 25.1%, respectively.
In multivariate analysis age older than 75 years was correlated
with a better biochemical response rate (P ¼ .047). RT as primary
treatment was correlated with lower response rate (P ¼ .04). Also
pre-SBRT PSA level had a negative effect on response rate if
between 4 and 10 ng/mL or > 10 ng/mL (P ¼ .04 and .05,
respectively; Table 4). Age older than 75 years, AD administered
up to 12 months, and pLN involvement were correlated with
longer PFS (P < .01, P ¼ .03, and P ¼ .01 if 1 pLN was involved
and P ¼ .02 if 2 pLNs were involved; Table 5). RT as primary
treatment and pre-SBRT PSA level between 4 and 10 ng/mL were
correlated with a lower PFS rate (P ¼ .03 and P ¼ .01,
respectively).
In the 57 patients treated with salvage SBRT alone with no
concomitant therapy, PSA response, stabilization, and progression
were observed in 38 (66.6%), 9 (16%), and 10 (17.5%) cases,
respectively. In 17 patients (36%) with progressive disease after
SBRT, AD was started in a median time of 7.2 months (range,
2.4e32.1 months). In 38% of patients AD was deferred by at least
1 year. AD was administered to those patients when not only PSA
value increased more than 10% over pre-SBRT values but a trend in
increasing was confirmed in a second PSA value 30 to 45 days later.
PFS was longer when AD was combined with SBRT for a period of
less than 12 months (median PFS in these patients: 28 months vs.
11 months; P ¼ .03 vs. P ¼ .24, in the patients with AD for > 12
months).
In the subgroup of patients who received concomitant AD PSA
response, stabilization, and progression were observed in 25
(73.5%), 1 (2.9%), and 8 (23.5%), respectively. Biochemical
complete response was found in 20 (58.8%) of those patients.
Furthermore, clinical progression was reported in 5 patients
(14.7%) who received concomitant AD after a median of 9.1
months (range, 3.9e28.3 months; Table 3).
Table 3 Treatment Response and Disease Progression (94 Patients With Follow-Up)
Characteristic All Patients Only Extrapelvic 1 Pelvic LN 2 Pelvic LNs
Patients With Follow-Up Data N ¼ 94 n ¼ 27 n ¼ 59 n ¼ 8
Biochemical Response to SBRT at First Follow-Up
All patients
CR 40 (42.6) 7 (25.9) 28 (47.5) 5 (62.5)
PR 24 (25.5) 7 (25.9) 16 (27.1) 1 (12.5)
SD 10 (10.6) 4 (14.8) 5 (8.5) 1 (12.5)
PD 20 (21.3) 9 (33.3) 10 (16.9) 1 (12.5)
Biochemical Response in Patients With No
Neoadjuvant and/or Concomitant Systemic
Therapy (CHT/AD)
N ¼ 57 n ¼ 14 n ¼ 39 n ¼ 4
CR 19 (33.3) 2 (14.3) 16 (41.0) 1 (25.0)
PR 19 (33.3) 5 (35.7) 13 (33.3) 1 (25.0)
SD 9 (15.8) 4 (28.6) 4 (10.3) 1 (25.0)
PD 10 (17.5) 3 (21.4) 6 (15.4) 1 (25.0)
Biochemical Response in Patients With
Neoadjuvant and/or Concomitant AD
N ¼ 34 n ¼ 12 n ¼ 18 n ¼ 4
CR 20 (58.8) 5 (41.7) 11 (61.1) 4 (100)
PR 5 (14.7) 2 (16.6) 3 (16.7) 0
SD 1 (2.9) 0 1 (5.6) 0
PD 8 (23.5) 5 (41.7) 3 (16.7) 0
Disease Progression During Follow-Up n ¼ 94 n ¼ 27 n ¼ 59 n ¼ 8
No 33 (35.1) 6 (22.2) 24 (40.7) 3 (37.5)
Biochemical 30 (31.9) 12 (44.4) 17 (28.8) 1 (12.5)
Clinical (locoregional lymph nodes) 11 (11.7) 3 (11.1) 6 (10.2) 2 (25.0)
Clinical with metastasis 20 (21.3) 6 (22.2) 12 (20.3) 2 (25.0)
Disease Progression During Follow-Up in Patients
With No Neoadjuvant and/or Concomitant
Systemic Therapy (CHT/AD)
N ¼ 57 n ¼ 14 n ¼ 39 n ¼ 4
No 17 (29.8) 3 (21.4) 14 (35.9) 0
Biochemical 15 (26.3) 4 (28.6) 10 (25.6) 1 (25)
Clinical (locoregional lymph nodes) 10 (17.6) 3 (21.4) 6 (15.4) 1 (25)
Clinical with metastasis 15 (26.3) 4 (28.6) 9 (23.1) 2 (50)
Disease Progression During Follow-Up in Patients
With Neoadjuvant and/or Concomitant AD
N ¼ 34 n ¼ 12 n ¼ 18 n ¼ 4
No 16 (47.1) 3 (25) 10 (55.6) 3 (75)
Biochemical 13 (38.2) 7 (58.3) 6 (33.3) 0
Clinical (locoregional lymph nodes) 1 (2.9) 0 0 1 (25)
Clinical with metastasis 4 (11.8) 2 (16.7) 2 (11.1) 0
Site of Metastasis After Lymph Node SBRT, n
Lymph nodes 10 3 5 2
Bones 5 1 4 0
Lymph nodes and bones 2 1 1 0
Muscles 1 0 1 0
Bones and lung 1 0 1 0
Bones and muscles 1 1 0 0
Status at Last Contact
Alive without disease 32 (34.0) 6 (22.2) 23 (39.0) 3 (37.5)
Alive with disease 60 (63.8) 20 (74.1) 35 (59.3) 5 (62.5)
Died of disease 1 (1.1) 1 (3.7) 0 0
Died 1 (1.1) 0 1 (1.7) 0
Follow-Up Duration, Months
Median (range) 18.5 (3-42) 17 (3-42) 19 (4-35) 21 (3-33)
Data are presented as n (%) except where otherwise noted.
Abbreviations: AD ¼ androgen deprivation; CHT ¼ chemotherapy; LN ¼ lymph node; SBRT ¼ stereotactic body radiotherapy.
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Figure 1 Progression-Free Survival (PFS) Curve, Including Biochemical and Clinical Progression
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e628All events of clinical failure were preceded by biochemical pro-
gression. Median PFS rates in patients treated for the single versus
multiple LNs were 16 and 11 months, respectively. Median PFS
rates in patients treated for eLN was 6 months, whereas for patients
treated for 1 or 2 pLNs median PFS was 18 and 15.5 months
(P ¼ .01 vs. P ¼ .02), respectively.
Toxicity
Follow-up examinations were performed every 6 to 9 months after
SBRT. In 88 patients (92.6%) no acute or late toxicity was observed.
Acute toxicity included urinary (6 and 1 Grade 1 and Grade 2
events, respectively) and rectal events (1 Grade 1). Late toxicity
included urinary (2 and 3 Grade 1 and Grade 2 events, respectively).
No toxicity was registered in the patients treated for eLN.
Discussion
To the best of our knowledge this is the largest series on isolated
LN recurrent PC treated with salvage SBRT. Our study showed thatFigure 2 Local Recurrence Cumulative Incidence (LRci)
- Clinical Genitourinary Cancer August 2017salvage SBRT is a safe approach in this scenario; it offers a high in-
field tumor control rate and a low toxicity profile. More than 50%
of patients were free of progression at 1 year after the SBRT and
one-third remained progression-free at 2 years. In patients who
received concomitant AD, PFS rates were 64.2% and 49.4% at 12
and 24 months, respectively, whereas in patients treated with SBRT
alone were 62.2% and 22.6%, respectively. Only 12 cases of in-field
progression (9.7%) were observed. A complete biochemical
response was observed in almost 33% of the lesions treated with
exclusive SBRT alone (no concomitant AD). The side effects
observed were mild and almost 93% of all patients did not expe-
rience any toxicity at all. Indeed, our series included unselected real-
world patients referred for low-burden metastasis-directed SBRT
(worse-prognosis patients like eLN, reirradiation, presence of more
than 1 LN, long pre-SBRT AD, castration-resistant disease etc, were
included). Such good results despite inclusion of numerous
unfavorable-prognosis patients makes SBRT a valuable salvage
treatment option for LN oligometastatic PC that should be
Table 4 Uni- and Multivariate Analysis of Factors Correlated With Better Biochemical Response to SBRT at First Follow-Up (N[ 94)
Variable n
Univariate Multivariatea
Positive Response (CR D PR D SD), % Pb OR (95% CI)c P (Wald c2)
All Patients 94 74 (78.7)
Primary Treatment .07
RRP 39 34 (87.2) 1
RRP with RT with or without AD 34 27 (79.4) 0.47 (0.11-2.02) .31
RT (BT) with or without AD 21 13 (61.9) 0.14 (0.02-0.87) .04
Initial GS (Total) .60d
6 15 10 (66.7)
7 48 40 (83.3)
8 26 20 (76.9)
Initial T .18d
1 10 6 (60)
2 29 24 (82.8)
3 50 41 (82.0)
4 2 2 (100.0)
Unknown 3 1
Treatment .92
Vero system (Mitsubishi-Brainlab) 84 66 (78.6)
CyberKnife (Accuray) 10 8 (80.0)
Age at SBRT, n .09
65 23 18 (78.3) 1
66-70 25 19 (76.0) 0.73 (0.44-1.81) .70
71-75 23 15 (65.2) 0.44 (0.28-1.42) .31
>75 23 22 (95.6) 14.3 (1.04-195) .047
AD .92
No 60 48 (80.0)
12 months 13 10 (76.9)
>12 months 21 16 (76.2)
KPS at SBRT .32
80-90 29 21 (72.4)
100 65 53 (81.5)
Pre-SBRT PSA (ng/mL) .01
<4 52 47 (90.4) 1
4-10 29 20 (69.0) 0.23 (0.06-0.90) .04
>10 12 7 (58.3) 0.18 (0.03-1.02) .05
SBRT as .94
1st Radiotherapy 85 67 (78.8)
Reirradiation 9 7 (77.8)
Lesions, n .27
1 70 57 (81.4)
2 24 17 (70.8)
Ln Pelvic Site .08d
0 (Extrapelvic) 27 18 (66.7) 1
1 59 49 (83.0) 1.47 (0.41-5.30) .56
2 8 7 (87.5) 11.9 (0.64-222.5) .1
Statistically significant P values are shown in bold.
Abbreviation: AD ¼ androgen deprivation therapy; BT ¼ brachytherapy; GS ¼ Gleason score; KPS ¼ Karnofsky performance status; Ln ¼ lymph node; PSA ¼ prostate serum antigen; RRP ¼ radical
retropubic prostatectomy; SBRT ¼ stereotactic body radiotherapy.
aIncludes the variables statistically significant after univariate analysis (P < .1).
bPearson c2.
cOR > 1 means higher probability of positive response to treatment.
dMantel-Haenszel test per trend.
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Table 5 Uni- and Multivariate Analysis of Factors Correlated With Longer Progression-Free Survival (94 Patients With Follow-Up)
Variable N
Univariate Multivariatea
Events, nb
Median Survival (95% CI),
Months Pc HR (95% CI) P (Wald c2)
All Patients 94 61 15 (9-18)
Primary Treatment .19
RRP 39 22 17 (8-30) 1
RRP with RT 34 22 17 (8-19) 0.91 (0.46-1.82) .79
RT (BT) 21 17 7 (5-18) 2.44 (1.10-5.40) .03
Initial GS (Total) .25
6 15 11 17 (3-21)
7 48 35 13 (7-17)
8 26 13 18 (5-inf)
Initial Td .84
1 10 7 9.5 (3-inf)
2 29 20 17 (8-21)
3 50 31 13 (6-18)
4 2 1 e
Treatment .63
Vero system (Mitsubishi-
Brainlab)
84 54 15 (9-19) 1
CyberKnife (Accuray) 10 7 17 (3-18) 0.56 (0.21-1.52) .26
Age at SBRT, n .15
65 23 18 9 (5-19) 1
66-70 25 17 13 (5-17) 0.89 (0.44-1.81) .88
71-75 23 14 14 (5-21) 0.63 (0.28-1.42) .27
>75 23 12 28 (10-31) 0.30 (0.13-0.72) <.01
AD .13
No 60 43 15 (7-18) 1
12 Months 13 6 28 (5-inf) 0.35 (0.14-0.88) .03
>12 Months 21 12 11 (5-inf) 0.62 (0.28-1.37) .24
KPS at SBRT .43
80-90 29 19 11 (5-18)
100 65 42 17 (9-19)
Pre-SBRT PSA (ng/mL) .22 (.01)b
<4 52 29 17 (13-21) 1
4-10 29 21 7 (4-18) 2.27 (1.18-4.35) .01
>10 12 10 8.5 (4-18) 1.15 (0.49-2.70) .75
SBRT as .64
1st Radiotherapy 85 57 15 (9-18)
Re-irradiation 9 4 Nonestimable
Lesions, n .89
1 70 45 16 (9-19)
2 24 16 11 (5-21)
Ln Pelvic Site .04
0 (Extrapelvic) 27 21 6 (4-17) 1
1 59 35 18 (10-24) 0.41 (0.21-0.81) .01
2 8 5 15.5 (5- inf) 0.23 (0.07-0.76) .02
Statistically significant P values are shown in bold.
Abbreviations: AD ¼ androgen deprivation therapy; BT ¼ brachytherapy; GS ¼ Gleason score; HR ¼ hazard ratio; inf ¼ infinite; KPS ¼ Karnofsky performance status; Ln ¼ lymph node;
PSA ¼ prostate serum antigen; RRP ¼ radical retropubic prostatectomy; RT ¼ radiotherapy; SBRT ¼ stereotactic body radiotherapy.
aIncludes the variables statistically significant after univariate analysis (P < .2).
bWilcoxon test.
cLog-rank test.
dWald c2.
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Barbara Alicja Jereczek-Fossa et alcompared with the standard salvage systemic therapy. Ongoing
studies will hopefully help to define the best treatment strategy for
oligometastatic and oligorecurrent PC.29
Stereotactic ablative body RT allows delivery of higher dose per
fraction with more significant cytotoxic efficacy and less dose to
normal tissues and organs at risk.30 This advanced technique
allowed us to implement the hypofractionation. Recently, interest in
SBRT has increased because of its potential in curative finality in the
oligometastatic setting. Hellmann and Weichselbaum31 first defined
the concept of oligometastatic that since has been considered as a
limited disease extension of up to 3 or 5 detectable metastases.32,33
Afterward, various studies evaluated the possible curative aim of
local treatments (ie, surgery, SBRT, high-intensity focused ultra-
sound etc) in this particular metastatic scenario. Importantly,
tumor-directed irradiation can produce a systemic antitumor ac-
tivity called the abscopal effect and this phenomenon could at least
partially explain the benefit of metastases-directed therapy on the
malignant disease course in general.34
In our institution 2 technologies are available for SBRT:
CyberKnife and Vero system. These 2 systems differ in image
guidance: Vero system is pretreatment CBCT-based but Cyber-
Knife is on the basis of infratreatment x-ray. Thus, CyberKnife
needs fiducials or spine tracking. CyberKnife is preferred when
particular attention to critical structures is required and spine
tracking is possible. If considering LN recurrence, the length of
treatment delivery with CyberKnife is higher than with the Vero
system. For all of these considerations we reserved selected cases for
CyberKnife. This choice showed no effect on treatment response,
however, the low number of patients treated with CyberKnife
makes the definitive comparison of these 2 SBRT approaches un-
feasible (Table 4).
Concerning PC, AD remains the gold standard treatment in the
metastatic setting. In higher-volume metastatic disease added use of
chemotherapy might increase tumor control, whereas the effect of
chemohormonal therapy in low-volume metastatic PC remains
unclear.4 AD can negatively affect the quality of life as well as the
metabolism, and increase occurrence of cardiovascular events and
metabolic syndrome.35,36 Therefore, local therapies are investigated
to delay the AD administration. Some authors have introduced the
concept of AD therapy-free survival, showing median time of AD
deferral of 38 months and AD-free survival of 82% at 1 year.15 In
our series, the response rates were similar in patients treated with
SBRT alone or with concomitant AD. On the contrary, AD had a
great effect on PFS: if AD was administered for a period of a
maximum of 12 months median PFS was 28 months versus 15
months of AD-free patients. This is in accordance with the review of
metastasis-directed therapy by Ost et al.5 The group with AD longer
than 12 months had a poor PFS (11 months). This finding might be
explained by the inclusion in the long-AD group the patients with
long history of PC (initial phase of castration-resistance?). SBRT
performed after a long period of AD might be less effective because
of radioresistance of heavily AD pretreated PC cells.36 Our patients
who were treated with SBRT alone, showed a median AD-free
survival of 7 months with the longest AD-free survival was 32
months. Importantly, in almost 40% of patients AD was deferred
by at least 1 year. However, patients treated with SBRT and
concomitant AD showed a higher rate of biochemical responses(73.5% vs. 66.6% of patients treated with SBRT alone) and lower
rate of progression (52.9% vs. 70.2% of patients treated with SBRT
alone). These differences need to be further investigated to define
the effect of the combined approach (SBRT with AD vs. SBRT or
AD alone) on primary (overall survival) and secondary (biochemical
control, etc) end points. Our series showed better outcome in pLN
recurrence. Patients with single-pLN recurrence experienced pro-
gression of disease later than the ones with 2-pLN recurrence
(median PFS of 18 vs. 15.5 months). eLN involvement was asso-
ciated with poor median PFS (6 months).
Regarding the management of progressive disease, in almost 50%
of our patients AD was started but in 20% of patients a new course
of SBRT was performed underlining that repeated SBRT is safe
without relevant events.
The local control rate we obtained with SBRT represents a mile-
stone: only 12 in-field progression events of 124 treated lesions. This
finding suggests relevant clinical implications such as preventing the
local compression and invasion of closer organs that is considerable
especially for PC long life expectancy. Moreover, most of the in-field
progressions occurred after 12 months from SBRT: that implies a
possible palliative reirradiation. The dose used in our study was
relatively low and atoxic, suggesting there is room for dose escalation
in future SBRT for isolated LN recurrence. Several investigators
discuss the necessity of single LN versus whole pelvis salvage irradi-
ation5,37,38: prospective comparison is warranted to define the best
treatment option. We remark on the favorable toxicity profile in our
series with no Grade > 2 acute or late events. Our longest follow-up
was 42 months so other updates of this cohort of patients are required
to evaluate possible late toxicities. To our knowledge no studies with
longer follow-up have been so far published.Conclusion
Stereotactic ablative body RT is a feasible approach to LN oli-
gorecurrent PC, offering excellent in-field tumor control and an
extremely low toxicity profile. At least half of the patients were
progression-free at 1 year after SBRT, one-third was progression-
free at 2 years. Among patients treated with SBRT alone, almost
40% of patients were AD-free at 1 year. Further investigations are
needed to identify the patients who would most benefit from this
treatment modality delivered alone or in combination with AD or
chemohormonal therapy.
Clinical Practice Points
 SBRT is feasible in prostate cancer lymph nodal oligorecurrences.
 Local control is very high with in field recurrences in less than
10% of cases.
 Toxicity profile is favorable with only G1-G2 toxicity in low
percentage of patients.
 This approach can delay androgen deprivation therapy admin-
istration: in our cohort only 36% of patients showed progressive
after SBRT alone and started ADT after 7 months.Acknowledgments
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